In vivo data published in Nature Biotechnology have reported that mRNA vaccines (RNActive) leveraging CureVac's RNA technology demonstrated immunogenicity and protection against virus infections.
The data published by CureVac and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute, Germany, revealed that mRNA vaccines provoke long-existing and protective immunity by producing balanced B- and T-cell responses targeting influenza A virus infections in different animal models.
RNActive vaccines are stable at high temperatures and can be easily supplied for different virus strains and subtypes that cause pandemic outbreaks.
CureVac chief executive officer Ingmar Hoerr said the results highlight the potential of mRNA further than cancer immunotherapy and confirm the capacity of RNActive vaccines in preventing infectious diseases.
"The synthetic nature of our RNActive vaccines reduces production time dramatically and allows for sequence-matched vaccines that can be produced quickly and reliably in a scalable process," Hoerr added
"Additionally, our vaccines can be stored at room temperature, thereby avoiding the cold-chain in contrast to all other vaccines on the market and making worldwide distribution of our vaccines logistically and financially attractive."
According to the study data, mRNA vaccine that encoded hemagglutinin (HA) of the influenza A/PuertoRico/8/1934 (PR8HA) strain was immunogenic.
In addition, sequence-matched, HA-specific vaccines showed protection against various lethal infections while single-dose immunization against influenza A/PR8 with a multi-component HA and NA mRNA vaccine also demonstrated complete protection.
The mRNA vaccine provided immunogenicity in newborns in addition to aged mice, ferrets, various animal models and pigs.